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SIGNIFICANCE
The NORdic PAtient survey of Psoriasis and Psoriasis 
arthritis (NORPAPP) collected data on disease prevalence 
and patient perceptions in Sweden, Denmark and Norway. 
Among 22,050 individuals questioned, the reported preva-
lence of psoriasis and/or psoriatic arthritis was 9.7% (5.7% 
physician-diagnosed plus 4.0% self-diagnosed only). Of pa-
tients with a physician’s diagnosis, 74.6% reported psoria-
sis alone, 10.3% psoriatic arthritis alone and 15.1% both. 
Patients with psoriatic arthritis perceived their disease to 
be more severe than those with psoriasis; patients with 
psoriatic arthritis and psoriasis reported greater disease 
severity than those with each condition alone. Psoriasis is 
common and has a large impact on patient’s life. 
Optimal clinical management of psoriasis and psoria-
tic arthritis (PsA) requires understanding of the impact 
on patients. The NORdic PAtient survey of Psoriasis 
and PsA (NORPAPP) aimed to obtain current data on 
disease prevalence and patient perceptions in Swe-
den, Denmark and Norway. Among 22,050 individuals 
questioned, the reported prevalence of psoriasis and/
or PsA was 9.7% (5.7% physician-diagnosed plus 4.0% 
self-diagnosed only); prevalence was similar in Sweden 
(9.4%) and Denmark (9.2%) but significantly higher in 
Norway (11.9%). Of those reporting a physician’s diag-
nosis, 74.6% reported psoriasis alone, 10.3% PsA alone 
and 15.1% both. Patients with PsA perceived their di-
sease to be more severe than those with psoriasis; pa-
tients with PsA and psoriasis reported greater disease 
severity than those with each condition alone. Patient’s 
perceptions of psoriasis severity correlated weakly 
(Spearman’s rho 0.42) with clinical severity; both pa-
tient perceptions and clinical measures are important in 
the assessment and management of psoriasis.
Key words: psoriasis; psoriatic arthritis; severity; prevalence; 
diagnosis. 
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Psoriasis (PsO) is a chronic, immune-mediated, in-flammatory skin condition that can have a major im-
pact on a patient’s health-related quality of life (HRQoL) 
(1). Estimates of the global prevalence of PsO in adults 
span a wide range (0.5–11.4%) and published figures vary 
according to the region (lower in Asia, higher in Europe), 
the population studied (general population, hospital 
cohort, patient registry) and the diagnosis and reporting 
method (2, 3). Estimates from studies in Norway, Swe-
den and Denmark suggest a relatively high prevalence 
of PsO in the Scandinavian region (2.2–11.4%) (4–10). 
Approximately 30–35% of individuals with PsO can also 
develop painful joint inflammation, known as psoriatic 
arthritis (PsA) (11–14). The timing of PsA symptoms 
is very variable, although PsA often manifests approx-
imately 10 years after the initial appearance of psoriasis 
symptoms on the skin (11) it can also precede them. 
In addition to controlling the clinical manifestations 
of PsO and PsA, optimal clinical management of these 
conditions requires a clear understanding of the impact 
of the disease on individual patients, taking into consi-
deration their own perception of severity and treatment 
success (15, 16). Numerous small patient surveys (sum-
marized by Lebwohl et al. in 2014 (17)) carried out 
over the past 50 years have provided useful information 
about the prevalence and treatment of PsO, but few were 
population-based and many lacked information on pa-
tient perceptions. To address this gap, the Multinational 
Assessment of Psoriasis and Psoriatic Arthritis (MAPP) 
survey was carried out in 2012 (17). While the MAPP 
survey provided much valuable information, it excluded 
the Nordic countries. 
The NORdic PAtient survey of Psoriasis and Psoriatic 
arthritis (NORPAPP) was conducted to gain a better 
understanding of patients with PsO and PsA in Sweden, 
Denmark and Norway. The purpose of the NORPAPP 
was to provide some insight into the main challenges 
faced by people living with PsO and PsA in these 
countries and to understand the patients’ perspectives 
on their disease, communication with the healthcare 
system and the different treatments prescribed. In this 
paper, we describe the NORPAPP survey population 
and results relating to disease diagnosis, prevalence and 
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patient perceptions of disease severity and extent. Future 
publications will describe the results relating to quality of 
life and contact with healthcare systems, and treatment 
use and patient satisfaction.
METHODS
Survey population
The survey was carried out by the market research firm YouGov 
during November and December 2015 using YouGov panels 
in Sweden, Denmark and Norway following the International 
Chamber of Commerce (ICC)/European Society for Opinion and 
Marketing Research (ESOMAR) International Code on Market, 
Opinion and Social Research and Data Analytics. The survey was 
conducted in accordance with ethical standards required in each 
participating country. 
YouGov panels are made up of a wide cross-section of individu-
als who have specifically opted in to participate in online studies 
(YouGov incentivizes participation by awarding points that can 
be redeemed for goods or entry to prize draws). An initial survey 
population was randomly selected from the YouGov panels using 
framing quotas based on the population census data to ensure 
inclusion of a representative sample of adults (aged 18–74 years) 
from each country. Quotas were set on the variables age, sex and 
region. The initial survey population was representative of these 
variables both overall and within each variable. 
The initial survey population were contacted by email and asked 
to select 1 of 4 possible responses to the question “Do you have any 
type of psoriasis or psoriatic arthritis?”: “Yes, and I am diagnosed 
by a physician”, “Yes, but I am not diagnosed by a physician”, “No, 
I don’t have any type of psoriasis” or “Don’t know/do not wish to 
answer”. Based on the response to this question, the target survey 
population (men and women aged 18–74 years who indicated that 
they had been diagnosed with PsO and/or PsA by a physician) 
were invited to participate in the full survey. 
Survey design
E-mail invitations were sent to the target survey population and 
respondents filled in their questionnaire answers online via an 
online link. The questionnaire included 44 questions covering 
perceived severity and symptoms, quality of life, contact with the 
healthcare system and treatment and medications. The full list of 
questions can be found in Appendix S11. 
Severity
The survey incorporated 2 questions that measured severity, one 
based on the respondents’ perception and 1 based on the area of 
PsO. Respondents with PsO alone and with PsO + PsA were asked 
to rate their disease on a 5-point scale from “not severe at all” to 
“extremely severe”. For analyses of the relationships between 
severity and other factors, the respondents’ reported 5-level self-
perception of severity was dichotomized to non-severe (“not severe 
at all” or “not particularly severe”) and severe (“quite severe”, 
“very severe” or “extremely severe”). Respondents were also asked 
to estimate the total area of their PsO symptoms, using the area of 
their own palms as a measurement unit, within the ranges: 0, 1–3, 
4–9, 10–19 and ≥ 20 palms. These data were then used to define 
estimates of conventional clinical severity by assuming that the 
area of 1 palm=1% of body surface area (BSA): mild (≤ 3% BSA), 
moderate (4–9% BSA) and severe (≥ 10 % BSA).
Statistical analysis
Data from the 3 countries were analysed together as a pooled da-
taset. Descriptive statistics were used to summarize demographic 
information for the surveyed population. The final survey data were 
weighted to the national profile of all adults within the included age 
group. Sample subpopulations were weighted to match national 
sex and age distributions. 
Significant deviations in responses between subgroups based on 
country, diagnoses, age, sex and patient organization membership 
were assessed using the χ2 test and z-test with Bonferroni correc-
tion (total α = 0.05) for comparisons of multiple answers within 
each question.
RESULTS
Study population
A total of 22,050 individuals were questioned about PsO 
and PsA: 87.4% responded that they did not have PsO 
or PsA; 9.7% reported having PsO and/or PsA (Sweden, 
9.4%; Denmark, 9.2%; Norway, 11.9%), which included 
5.7% that were physician-diagnosed and 4.0% that were 
self-diagnosed only (Table I). The proportions of respon-
ses were broadly comparable across countries, although 
the prevalence of physician-diagnosed PsO and/or PsA 
reported by Norwegian respondents was significantly 
higher than that reported by Swedish respondents. The 
prevalence of self-diagnosed PsO and/or PsA was also 
significantly (p < 0.05) higher for Norwegian respon-
dents than for both Danish and Swedish respondents. 
The proportion of respondents that reported having 
self-diagnosed PsO and/or PsA was lower in the older 
age group (45–74 years; 33%) than in the younger age 
group (18–44 years; 48%). 
All individuals who reported physician-diagnosed PsO 
and/or PsA were invited to participate in the full survey 
and 1,221 (96.6%) responded. Population demographics 
and disease states are provided in Table I. There were 
approximately equal numbers of male and female respon-
dents, but slightly more older than younger respondents. 
Membership of a patient organization was reported by 
21.0% of respondents overall; a greater proportion of 
patients with PsA ± PsO were members of patient orga-
nizations compared with patients with PsO alone.
Diagnosis
Overall, for the pooled data set, PsO alone was the most 
frequently reported diagnosis, with fewer respondents 
reporting a diagnosis of PsA alone or combined PsA + 
PsO (Table I). The estimated prevalence of physician-
diagnosed PsO was 5.1% and that of PsA was 1.5%. 
In Denmark, there was a significantly (p < 0.05) higher 
proportion of respondents reporting PsO alone and a 
significantly (p < 0.05) lower proportion of respondents 
reporting of PsA + PsO compared with Sweden and 
Norway (Table I). Within the pooled population of re-
spondents, a significantly (p < 0.05) higher proportion of 1https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3017
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those with PsA + PsO were in the older age group (45–74 
years). Membership of a patient organization was more 
common among respondents with PsA and PsA + PsO 
than among those with PsO alone.
A significantly (p < 0.05) higher proportion of respon-
dents with PsO alone were diagnosed within one year 
of first noticing symptoms compared with respondents 
diagnosed with PsA alone (Fig. 1a). Twice as many re-
spondents reporting PsA alone had a delay of 10 years or 
more before they were diagnosed compared with respon-
dents reporting PsO alone. The pattern was similar for 
respondents with PsA + PsO (Fig. 1b). Just over a third 
of respondents (39.3%) with PsA + PsO were diagnosed 
for each condition within the same elapsed time after the 
occurrence of symptoms, but more respondents (44.1%) 
had shorter delays for the diagnosis of PsO than for PsA 
and a few (16.6%) had shorter delays for the diagnosis 
of PsA than for PsO.
Psoriasis
Severity. Most respondents with PsO alone (72.7%) 
considered their condition to be “not severe at all” or 
“not particularly severe” (Fig. 2a). Relative to respon-
dents with PsO alone, there were significantly (p < 0.05) 
higher proportions of respondents with PsO + PsA who 
considered their condition to be “quite severe” or “very 
severe”. The proportion of respondents with PsO alone 
considering their condition to be severe were higher 
among members of patient organizations compared with 
non-members (49.2% vs. 23.3%, p < 0.05). PsO severity 
based on the estimated % BSA involved showed a similar 
pattern (Fig. 2b). The 2 severity measures correlated mo-
derately (Spearman’s rank correlation 0.42) (Table II).
Symptoms. Flare-ups of PsO were reported to occur quar-
terly or more often by 61.1% of respondents and every 6 
months or less often by 33.8% of respondents (the ques-
tion defined flare-ups as “periods when symptoms have 
worsened”). Common locations of PsO symptoms were 
the scalp and the elbow (Table III). Several locations 
were affected in a significantly (p < 0.05) greater propor-
tion of respondents with PsO + PsA compared with PsO 
alone (Table III). PsO symptoms at most locations were 
reported by a significantly (p < 0.05) greater proportion of 
respondents who perceived their symptoms to be severe 
(“quite severe” or worse) vs. non-severe (“not parti-
cularly severe” or better) (Table IV). The most common 
Table I. Demographics of base population (with responses to the initial survey question “Do you have any type of psoriasis or psoriatic arthritis?”, 
which had 4 mutually exclusive answer options: “Yes, and I’m diagnosed by a physician”; “Yes, but I’m not diagnosed by a physician”; “No, I don’t 
have any type of psoriasis”; “Don’t know/do not wish to answer”) and demographics and disease states of the population reporting physician-
diagnosed PsO/PsA who responded to the extended survey. Base numbers were weighted to match national distributions of sex and age.
Total Sweden Denmark Norway
Total number asked about PsO/PsA, NTot 22,050 9,781 8,871 3,398
Female (unweighted), n 10,922 (11,243) 4,831 (4,661) 4,426 (4,778) 1,665 (1,804)
Male (unweighted), n 11,128 (10,807) 4,950 (5,120) 4,445 (4,093) 1,733 (1,594)
Aged 18–44 years (unweighted), n 10,795 (9,193) 4,819 (3,934) 4,229 (3,606) 1,747 (1,653)
Aged 45–74 years (unweighted), n 11,255 (12,857) 4,962 (5,847) 4,642 (5,265) 1,651 (1,745)
Diagnosed by a physician (invited to answer more questions), % of NTot (n) 5.7 (1,264) 5.3 (521)
a 5.8 (513)a,b 6.8 (230)b
Female, % 51.6 51.2 53.4 48.2
Aged 18–44 years/45–74 years, % 44.8/55.2* 44.4/55.6 43.6/56.4 48.4/51.6
Self-diagnosed only, % NTot (n) 4.0 (875) 4.1 (388)
a 3.4 (305)a 5.1 (174)b
Female, % 45.3* 47.1 44.0 43.5
Aged 18–44 years/45–74 years, % 60.0/40.0* 59.4/40.6 59.8/40.2 61.5/38.5
Do not have PsO or PsA, % NTot (n) 87.4 (19,275) 87.8 (8,587)
a 88.5 (7,854)a 83.4 (2,834)b
Female, % 49.9* 49.7 50.2 49.7
Aged 18–44 years/45–74 years, % 48.3/51.7* 48.6/51.4 47.2/52.8 50.3/49.7
No answer, % NTot (n) 2.9 (636) 2.8 (277)
a 2.2 (198)b 4.7 (161)c
Female, % 39.2* 39.5 35.8 42.7
Aged 18–44 years/45–74 years, % 63.3/36.7* 65.3/34.7 59.7/40.3 64.3/35.7
Invited participants who responded, % NTot (n) 1,221 (96.6) 497 (95.4) 506 (98.5) 218 (94.8)
Female, % 51.1 50.3 53.2 47.9
Aged 18–44 years/45–74 years, % 44.9/55.1 44.8/5.2 43.6/56.4 48.2/51.8
Member of patient group, %d 21.0 22.5 17.9 24.5
Only psoriasis, n
 
(%) 911 (74.6) 342 (68.8)
a
411 (81.2)
b
158 (72.6)
a
Female, % 50.6 50.8 52.8 44.5
Aged 18–44 years/45–74 years, % 45.7/54.3 45.9/54.1 44.7/55.3 47.8/52.2
Member of patient group, %d 14.6 17.2 11.0 18.6
Only psoriatic arthritis, n (%) 126 (10.3) 56 (11.3)a 41 (8.1)a 29 (13.4)a
Female, % 46.7 52.1 39.2 46.8
Aged 18–44 years/45–74 years, % 51.3/48.7 50.3/49.7 45.6/55.4 61.3/38.7
Member of patient group, %d 46.5 39.4 51.6 52.5
Both psoriasis and psoriatic arthritis, n (%) 184 (15.1) 99 (19.9)a 54 (10.8)b 31 (14.0)a,b
Female, % 56.2 47.5 66.4 66.2
Aged 18–44 years/45–74 years, % 36.7/63.3* 38.1/61.9 33.7/66.3 37.8/62.2
Member of patient group, %d 35.3 32.5 45.0 27.5
a,b,cWithin each row where the data between 2 countries does not differ significantly, the data in each country column is marked with the same letter. Different letters 
within the row indicate where data for countries does differ significantly (Bonferroni corrected z-test, total α=0.05). dDenominators for “member of patient group” % 
were lower as some respondents did not answer.
*Denotes a significant difference between sex or age-range subgroups within the total of participants (Bonferroni corrected z-test, total α=0.05). 
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PsO-related symptoms equally affecting those with PsO 
alone and those with both PsO + PsA were flaking/scales 
and itching (Fig. 3). Most of the less frequent symptoms 
of PsO, which are also commonly associated with PsA 
(e.g. dactylitis, enthesitis), were reported at significantly 
(p < 0.05) and substantially greater rates by respondents 
with PsO + PsA, as expected (Fig. 3). 
The 2 most common symptoms were reported signifi-
cantly more often in respondents whose symptoms were 
perceived to be severe vs. non-severe (76.9% vs. 63.3% 
for itching; 76.3% vs. 66.9% for flaking/scales; p < 0.05). 
However, itching and flaking/scales were not signifi-
cantly different across the % BSA-based severity grades 
(for mild/moderate/severe: itching, 66.6%/72.7%/68.8%; 
flaking/scales, 68.5%/77.5%/76.9%). Most symptoms 
were significantly more commonly reported by respon-
dents with more severe symptoms using both measures 
of severity; however, plaques were only significantly 
related to the % BSA. The most notable differences were 
in pain and bleeding symptoms, which occurred at least 3 
Fig. 1. Delay in diagnosis from the onset of symptoms for respondents: (a) reporting psoriasis (PsO) alone vs. those reporting psoriatic arthritis 
(PsA) alone; and (b) reporting both PsA and PsO. *Significant difference between PsO and PsA groups (Bonferroni corrected z-test, total α=0.05).
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Fig. 2. Severity measures for psoriasis (PsO) symptoms, split by respondents reporting PsO and psoriatic arthritis (PsA) vs. PsO alone. (a) 
Respondent reported perception of severity of PsO symptoms. All categories except “extremely severe” are significantly different between PsO alone and 
PsO + PsA groups (Bonferroni corrected z-test, total α=0.05). (b) Estimated clinical severity based on the patient reported percentage of body surface 
area (% BSA) affected, which was derived from the reported sum of palm-sized areas of PsO. All categories are significantly different between PsO alone 
and PsO + PsA groups (Bonferroni corrected z-test, total α=0.05).
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times more often in respondents whose symptoms were 
severe vs. non-severe (46.9% vs. 12.1% for pain; 34.1% 
vs. 9.2% for bleeding; p < 0.05). A similar relationship 
was found for the % BSA-based severity measures: both 
pain and bleeding occurred at least 3 times more often in 
respondents with severe vs. mild symptoms (54.3% vs. 
18.1% for pain; 51.5% vs. 12.9% for bleeding; p < 0.05).
Psoriatic arthritis
Severity. Most respondents with PsA ± PsO (58.7%) 
considered their condition to be “quite severe” or worse 
(Fig. 4a). A significantly (p < 0.05) greater proportion of 
respondents with PsA + PsO considered their condition 
to be “extremely severe” compared with those with PsA 
alone (Fig. 4b).
Symptoms. Among those with PsA ± PsO, current joint 
pain was reported by 48.5% of respondents, and 28.3% 
reported experiencing joint pain in the past 12 months. 
Current joint pain was reported by a significantly greater 
proportion of respondents with PsA ± PsO whose symp-
toms were severe vs. non-severe (61.9% vs. 31.7%; 
p < 0.05). Respondents with PsA ± PsO who indicated 
that they had experienced joint pain mostly reported the 
most bothersome sites of pain to be in their fingers/hands 
(57.1%) and in their knees (48.4%). 
Joint pain was also reported by respondents who had 
not been diagnosed with PsA. Among patients who re-
ported being diagnosed with PsO alone, 23.8% indicated 
that they had current joint pain and 18.1% said that they 
had experienced pain or soreness in their joints in the 
past 12 months. 
DISCUSSION
The NORPAPP survey was based on 1,221 respondents 
from a population representative sample who reported 
physician-diagnosed PsO and/or PsA in Sweden, Den-
mark and Norway. The overall regional prevalence of 
self-reported PsO and/or PsA in this survey population 
was 9.7%, which included 5.7% physician-diagnosed 
cases and 4.0% self-diagnosed only. For physician-
diagnosed cases, the prevalence of PsO was 5.1% and 
that of PsA was 1.5% (0.9% reported both). 
Table II. Distribution of respondent reported perception of severity of psoriasis symptoms for each estimated clinical severity category
Estimated percentage of BSA based 
measure of severity
Patient’s perception of psoriasis severity, %
Not severe at all Not particularly severe Quite severe Very severe Extremely severe
Mild (≤ 3% BSA, n = 895) 24.7 54.4 18.2   2.0 0.6
Moderate (4–9% BSA, n = 129) 3.7 26.7 49.9 14.7 5.0
Severe (≥ 10% BSA, n = 48) 1.9 11.1 56.4 22.8 7.8
The estimates of clinical severity were based on estimates of the percentage of body surface area (% BSA) affected, which was derived from the respondent reported 
sum of palm-sized areas of psoriasis (n=1,072).
The Spearman’s rank correlation between the 2 methods of severity measurement was 0.42.
Table III. Location of symptoms for respondents reporting psoriasis 
(PsO) alone or combined with psoriatic arthritis (PsA) 
Location, %
Total 
(n = 1,095)
PsO alone
(n = 911)
PsA + PsO
(n = 184)
Scalp 54.9 53.4 62.2
Elbow 40.4 39.0 47.0
Other body location 27.1 26.7 29.2
Ears 24.0 21.9* 34.2*
Knees 23.0 21.4 30.6
Nails 18.6 16.0* 31.1*
Fingers 15.7 14.2 23.0
Palm of hands or sole of feet 14.9 14.1 18.7
Ankles 14.3 13.2 19.8
Back/spine 14.2 13.6 17.4
Genitals 11.7   9.4* 23.1*
Chest 11.4 10.5 16.0
Wrist 10.2   9.2 15.3
Hips 9.5 9.4   9.9
Toes 9.3 8.1 15.1
In skin folds (inverse psoriasis) 8.6 7.0* 16.4*
Arm pit 8.4 8.1   9.9
The bend of the arm 8.3 8.3   8.7
Heels 8.3 7.8 10.8
Shoulders 7.1 6.7   9.0
Neck 5.1 4.0* 10.2*
I have not experienced any symptoms 
in the past 12 months
2.6 3.0   0.7
Do not know/do not wish to answer 0.9 0.7   1.8
*Significant difference between PsO and PsA + PsO groups (Bonferroni corrected 
χ2 test, total α=0.05).
Table IV. Location of symptoms for respondents reporting psoriasis 
in relation to severity
Location
Total 
(n = 1,089) 
%
“Not particu-
larly severe” 
or better
(n = 763) 
%
“Quite 
severe” 
or worse
(n = 326) 
%
Scalp 55.0 52.3 61.5
Elbow 40.6 34.8* 54.1*
Other body location 27.2 23.7* 35.5*
Ears 24.1 18.2* 37.8*
Knees 23.1 17.3* 36.6*
Nails 18.7 12.9* 32.2*
Fingers 15.7 11.7* 25.1*
Palm of hands or sole of feet 15.0 12.0* 22.0*
Ankles 14.4 10.9* 22.5*
Back/spine 14.2 7.9* 28.9*
Genitals 11.7 9.1* 17.9*
Chest 11.4 6.9* 22.0*
Wrist 10.3 7.0* 17.8*
Hips 9.5 4.8* 20.6*
Toes 9.3 5.1* 19.3*
In skin folds (inverse psoriasis) 8.6 6.1* 14.5*
Arm pit 8.4 3.8* 19.1*
The bend of the arm 8.4 5.7* 14.6*
Heels 8.4 5.5* 15.0*
Shoulders 7.1 3.1* 16.6*
Neck 5.1 2.6* 11.0*
I have not experienced any symptoms 
in the past 12 months
2.7 3.8* 0.0*
Do not know/do not wish to answer 0.5 0.5 0.4
*Significant difference between severity groups (Bonferroni corrected χ2 test, 
total α=0.05).
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This study was based entirely on self-reported data, 
including self-reporting of a physician’s diagnosis and 
self-reporting of clinical symptoms such as affected % 
BSA. The NORPAPP survey results were subject to the 
limitations inherent to this type of respondent survey. 
Responses rely on the respondent’s recall of facts and 
interpretation of the questions; because the survey was 
carried out online, there was no scope for questions and 
clarification. While the active sampling and weighting of 
the data was carried out to ensure that the sample popula-
tion was truly representative of the populations of each 
country, the use of respondents registered with YouGov 
may have introduced some bias. These individuals have 
proactively registered to take part in surveys and, al-
though this leads to very high response rates (> 95% for 
all questions), they may not be entirely representative 
of the broader population. This is perhaps illustrated 
by the relatively high proportion of members of patient 
organizations (21.0% of respondents). A strength of the 
study is the large number of respondents from across the 
region, which also allows for comparison between indi-
vidual countries. Pooling of data from the Scandinavian 
countries included in this report was justified because of 
the very similar healthcare systems and access to treat-
ments across all 3 countries (18). 
PsO prevalence data reported in the literature varies 
widely and comparison across studies, even within geo-
graphical regions, can be complicated by differences in 
the type of study population, the method of assessment 
and the time-frame assessed. A systematic review of stu-
dies published up to November 2015 (3) found the lowest 
prevalence (0.51–1.13%) reported in the USA, based 
on Medicare claims made in 2011 (19), and the highest 
prevalence (11.4%) reported in North Norway, based on 
self-reported lifetime prevalence in a population survey 
carried out in 2007 to 2008 (the sixth Tromsø study) (10). 
Although the total self-reported prevalence in the cur-
rent study was consistent with the overall self-reported 
prevalence in the sixth Tromsø study, these levels of pre-
valence seem to be generally higher than the self-reported 
7.1% 31.9% 38.3% 15.7% 4.7%
2.4%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Total
(n = 310)
Not severe at all Not particularly severe Quite severe Very severe Extremely severe Don’t know / do not wish to answer
6.2%
7.7%
36.0%
29.0%
42.7%
35.3%
12.9%
17.6%
1.1%
7.1%
1.1%
3.3%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
PsA alone
(n = 126)
PsA + PsO
(n = 184)
Not severe at all Not particularly severe Quite severe Very severe Extremely severe Don’t know / do not wish to answer
a
b
*
*
Fig. 4. Respondent reported perception of severity of psoriatic arthritis (PsA) symptoms for: (a) all respondents reporting PsA (total); and 
(b) split by patients reporting PsA alone and those reporting both PsA and PsO. *Significantly different (Bonferroni corrected z-test, total α=0.05).
Fig. 3. Distribution of symptoms due to psoriasis (PsO, 
on skin, nails or scalp) experienced within the prior 
12 months by all respondents reporting PsO (total), 
those reporting PsO alone, and those reporting both 
PsO and psoriatic arthritis (PsA). *Significant difference 
between PsO alone and PsO + PsA groups (Bonferroni 
corrected χ2 test, total α=0.05).
2.2%
2.2%
6.2%
25.8%
17.5%
34.4%
19.7%
23.4%
33.8%
39.2%
29.5%
48.4%
32.3%
52.8%
70.0%
70.3%
0.4%
6.2%
2.1%
5.3%
9.2%
6.0%
9.5%
15.2%
13.7%
16.2%
19.6%
17.1%
24.0%
45.2%
66.7%
69.4%
0.7%
5.5%
2.8%
8.8%
10.6%
10.7%
11.2%
16.6%
17.1%
20.1%
21.3%
22.4%
25.4%
46.5%
67.2%
69.5%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Don’t know / do not wish to answer
I have not experienced any
symptoms in the past 12 months
Other symptoms*
Tender or swollen tendons (e.g. on
the heel, so-called enthesitis)*
Pustules (pus-ﬁlled blisters)*
Swollen ﬁngers or toes (e.g. sausage
digits, so-called dactylitis)*
Depression or anxiety*
Bleeding
Nail psoriasis*
Fatigue*
Burning*
Pain*
Plaque
Redness
Itching
Flaking/scales
Total (n = 1095)
PsO alone (n = 911)
PsO + PsA (n = 184)
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prevalence from other reports, for example, a prevalence 
of 3.9% was reported in a 2004 to 2005 nationwide skin-
disease survey in Sweden (6) and 5.8% was reported in 
the third survey of the Nord-Trøndelag Health Study in 
Norway (HUNT3, 2006–2008) (4). Notably, in our initial 
survey population, self-diagnosed individuals made up 
40% of the total respondents who stated that they had PsO 
and/or PsA. In the sixth Tromsø study, the self-reported 
prevalence of physician-diagnosed PsO was 9.9% and 
the total self-reported prevalence of PsO was 11.4%, 
so, of the respondents reporting that they had PsO, 13% 
were self-diagnosed only (10). Conversely, the HUNT3 
study, a validation exercise in which a representative 
subset of respondents took part in a clinical interview 
and extensive skin examination using strict definition 
criteria, revealed a higher prevalence of PsO than the 
self-reported prevalence (8.0% vs. 5.8%) (4). However, 
among the 16 “false-negative” respondents who were 
diagnosed with PsO in the validation examination, 12 
had mild scalp PsO only. Exclusion of these respondents 
reduced the prevalence of PsO in the validation study 
to 5.2%. Also, notably in our study, the proportion of 
respondents who were self-diagnosed was lower in the 
older age group (45–74 years; 33%) than in the younger 
age group (18–44 years; 48%). This may be a result of 
increased secondary diagnosis among older respondents 
who are more likely to visit a physician for other health 
issues or it may reflect a longer duration of disease in the 
older group, providing more time to seek and obtain a di-
agnosis. It is also possible that younger respondents were 
more likely to have self-diagnosed based on information 
from the Internet. For most respondents who specified 
the timing of their diagnosis, there was a delay of at least 
one year between the onset of symptoms and diagnosis 
by a physician. The delay in diagnosing PsA alone was 
greater than the delay in diagnosing PsO alone, which 
might be expected given the potential range of causes for 
the symptoms of PsA. Perhaps less expected was that the 
increased delay in PsA diagnosis was also evident in the 
population of respondents with PsA + PsO, since most 
would have had PsO first (11, 20). This is consistent with 
the findings of the PREPARE study, which found that 
almost a third of patients (30.0%) with PsO seen in 34 
dermatology centres in Europe and North America had 
PsA as determined by rheumatologists, and more a third 
(41.1%) of these patients with PsA had not previously 
been given the diagnosis (21). These observations are 
also consistent with the fact that of the patients in our 
survey who reported a diagnosis of PsO only, 23.8% 
indicated that they were currently experiencing joint 
pain. It is possible that some of these patients may have 
been suffering from undiagnosed PsA. 
The reported diagnosis of 126 respondents with PsA, 
but not PsO, representing 40.6% of all respondents with 
PsA, seems high. While PsA can occur in people without 
skin PsO (22), particularly in those with relatives with 
PsO, the proportion of respondents with PsA who initially 
develop joint symptoms in the absence of any identified 
signs of PsO is generally reported to be 15–30% (11). In 
the MAPP survey, 21% of respondents with PsA reported 
that they had experienced joint symptoms before they 
experienced any skin symptoms (23). There could be 
several reasons for the higher proportion of respondents 
with PsA, but not PsO in this survey; for example, the 
psoriatic component of the diagnosis could be based on 
family history, while there was no active PsO at the time 
of diagnosis or the time of the survey, or the respondent 
may have been seen first by a rheumatologist who did not 
flag the PsO as a specific separate diagnosis. A limitation 
of our survey is that data were not collected about the 
relative timing of diagnosis of PsO and PsA in respon-
dents reporting both conditions. 
Comparing self-assessed severity with the patient esti-
mated % BSA-based clinical severity of PsO symptoms 
confirmed that the clinical measure is of limited value 
in capturing respondent perceptions: within each cate-
gory of clinical severity there was a substantial spread 
of respondent perceived severity. Self-assessed severity 
was significantly related to symptoms of itching and 
flaking/scales, whereas % BSA-based clinical severity 
was not. For symptoms of PsO, both the respondents’ 
perception and clinical severity were significantly worse 
for respondents who also had PsA. Overall, respondents 
perceived PsA symptoms to be more severe than those of 
PsO. In general, respondents’ perception of the severity 
of PsA symptoms followed a similar pattern, whether 
or not they also had PsO. However, among the small 
group of respondents who described their PsA symptoms 
as “extremely severe”, a significantly (p < 0.05) higher 
proportion had PsO + PsA compared with PsA alone. The 
degree of alignment between respondent perceptions of 
the severity of PsO and % BSA is generally in line with 
results from the MAPP survey, which showed that while 
dermatologists judged severity primarily on the size and 
location of lesions, patients judged severity by a broader 
range of factors, led by itching (24). In the MAPP sur-
vey, respondents were asked to rate the severity of their 
disease at its worst on a 1–10 scale from “very mild” to 
“very severe”, which was then recorded into a 3-level 
measure (mild, moderate, severe): 27% of respondents 
with PsO rated their disease as “severe” (defined as 
8–10 on the scale), whereas the majority of respondents 
with PsA (53% of the subset who had joint pain) rated 
their disease as “severe” (23). Although this scale does 
not map onto the NORPAPP data perfectly, as both the 
divisions and language are different, the findings are 
compatible: 27% of the NORPAPP PsO alone group rated 
their symptoms “quite severe” or worse, as did 59% of 
the PsA ± PsO group.
In conclusion, the results of this survey indicate that 
there is a high burden of PsO and PsA in all 3 of the 
Scandinavian countries included in this study. Patients’ 
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perceptions of the severity of their condition did not 
correlate well with clinical severity, which suggests that 
new approaches to the assessment and management of 
PsO may be beneficial.
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